Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Nov;19(11):1969-76.
doi: 10.1038/sj.leu.2403890.

The Combination of Intermediate Doses of Thalidomide With Dexamethasone Is an Effective Treatment for Patients With Refractory/Relapsed Multiple Myeloma and Normalizes Abnormal Bone Remodeling, Through the Reduction of sRANKL/osteoprotegerin Ratio

Affiliations
Clinical Trial

The Combination of Intermediate Doses of Thalidomide With Dexamethasone Is an Effective Treatment for Patients With Refractory/Relapsed Multiple Myeloma and Normalizes Abnormal Bone Remodeling, Through the Reduction of sRANKL/osteoprotegerin Ratio

E Terpos et al. Leukemia. .

Abstract

The aim of this study was the evaluation of the effect of intermediate doses of thalidomide with dexamethasone (Thal/Dex) on disease course and bone disease in patients with refractory/relapsed myeloma who were under zoledronic acid therapy. We studied 35 patients, who received thalidomide at a dose of 200 mg/daily. We measured, pre-, 3 and 6 months post-treatment soluble receptor activator of nuclear factor-kappaB ligand (sRANKL), osteoprotegerin (OPG), osteopontin (OPN), markers of bone resorption and formation. Before treatment, patients had increased levels of sRANKL/OPG ratio, bone resorption markers and OPN, while they had suppressed bone formation. The pretreatment sRANKL/OPG ratio correlated with the extent of bone disease. Thal/Dex administration resulted in a significant reduction of sRANKL/OPG ratio, and bone resorption. Bone formation, OPG and OPN did not show any alteration. Changes of sRANKL/OPG ratio correlated with changes of bone resorption markers. Thal/Dex was given for a median time of 10 months and the median follow-up period was 22 months. The response rate was 65.7%. The median survival was 19.5 months. beta2-microglobulin, type of response and International Staging System predicted for survival. These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio.

Similar articles

See all similar articles

Cited by 18 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback